AIM ImmunoTech
13 hedge funds and large institutions have $4.91M invested in AIM ImmunoTech in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.
186% more capital invested
Capital invested by funds: $1.72M → $4.91M (+$3.19M)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.16M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.1M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$21.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.1K |
| 5 |
Renaissance Technologies
New York
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$10K |
| 2 |
State Street
Boston,
Massachusetts
|
-$9K |
| 3 |
Bank of New York Mellon
New York
|
-$8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5K |
| 5 |
Goldman Sachs
New York
|
-$3K |
AIM Hedge Fund Activity: Q3 2016 in Review
13 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2016, worth a combined $4.91M — up 186% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AIM and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.16M. The largest seller was Guggenheim Capital, exiting entirely with an estimated $10K sold.
- 13 institutional investors held AIM ImmunoTech (AIM) as of Q3 2016, down from 14 in Q2 2016.
- Funds reported $4.91M of AIM ImmunoTech stock for Q3 2016, up 186% quarter-over-quarter.
- 3 funds opened new AIM ImmunoTech positions in Q3 2016 and 4 closed out, a net change of -1 holder.
- The largest AIM ImmunoTech buyer in Q3 2016 was Sabby Management, an estimated $2.16M added.
- The largest AIM ImmunoTech seller in Q3 2016 was Guggenheim Capital, an estimated $10K sold.
Based on aggregated 13F filings for Q3 2016.